Evidence map›Paper›PMID 30256525›Full record

ArticlePediatric blood & cancer2019

Increased clinical trial enrollment among adolescent and young adult cancer patients between 2006 and 2012-2013 in the United States.

Helen M Parsons, Dolly C Penn, Qian Li, Rosemary D Cress, Brad H Pollock, Marcio H Malogolowkin, Ted Wun, Theresa H M Keegan

Abstract read
In one paragraph

Article in Pediatric blood & cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Body Composition at Diagnosis and Early Response in Pediatric Hodgkin Lymphoma.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2025
    Article
  8. Review
  9. Article
  10. Article
  11. Challenges to successful outcomes in AYAs with ALL and potential solutions.Hematology. American Society of Hematology. Education Program · 2023
    Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Helen M ParsonsDivision of Health Policy and Management, University of Minnesota, Minneapolis, Minnesota.ORCID 0000-0003-3822-9858
Dolly C PennNational Cancer Institute, Bethesda, Maryland.
Qian LiCenter for Oncology Hematology Outcomes Research and Training (COHORT) and Division of Hematology and Oncology, University of California Davis School of Medicine, Sacramento, California.
Rosemary D CressPublic Health Institute, Cancer Registry of Greater California, Sacramento, California.
Brad H PollockDepartment of Public Health Sciences, University of California Davis School of Medicine, Davis, California.
Marcio H MalogolowkinDepartment of Pediatrics, University of California Davis School of Medicine, Sacramento, California.
Ted WunCenter for Oncology Hematology Outcomes Research and Training (COHORT) and Division of Hematology and Oncology, University of California Davis School of Medicine, Sacramento, California.
Theresa H M KeeganCenter for Oncology Hematology Outcomes Research and Training (COHORT) and Division of Hematology and Oncology, University of California Davis School of Medicine, Sacramento, California.

Funding

Minnesota Population Center Science and Technical CoreP2CHD041023 · NICHD · UNIVERSITY OF MINNESOTA · PI THERESA LOUISE OSYPUK · 2016 to 2026
$4.3M
NCI NIH HHS HHSN26120100NCI NIH HHS HHSN261201000024CNCI NIH HHS HHSN261201000025CNCI NIH HHS HHSN261201000026CNCI NIH HHS HHSN261201000027CNCI NIH HHS HHSN261201000028CNCI NIH HHS HHSN261201000029CNCI NIH HHS HHSN261201000030CNCI NIH HHS HHSN261201000031CNCI NIH HHS HHSN261201000032CNCI NIH HHS HHSN261201000033CNCI NIH HHS HHSN261201000034CNCI NIH HHS HHSN261201000035CNCI NIH HHS HHSN261201000035INCI NIH HHS HHSN261201000037CNCI NIH HHS HHSN261201000140CNICHD NIH HHS P2C HD041023
6 · The paper itself

Abstract

backgroundStagnant outcomes for adolescents and young adults (AYAs) 15-39 years of age with cancer are partly attributed to poor enrollment onto clinical trials. Initiatives have focused on increasing accrual, but changes at the population-level are unknown. We examined patterns of clinical trial participation over time in AYA patients with cancer. PROCEDURE: We utilized medical record data from AYAs in two population-based National Cancer Institute Patterns of Care Studies identified through the Surveillance, Epidemiology and End Results Program. Among 3135 AYAs diagnosed with non-Hodgkin lymphoma (NHL), Hodgkin lymphoma, acute lymphoblastic leukemia (ALL), and sarcoma, we used multivariate logistic regression to evaluate patient and provider characteristics associated with clinical trial enrollment. Interaction terms evaluated variation in clinical trial enrollment across patient and provider characteristics by year of diagnosis.

resultsFrom 2006 to 2012-2013, clinical trial participation increased from 14.8% to 17.9% (P < 0.01). Adjusting for patient and provider characteristics, we found lower clinical trial enrollment among those who were older at diagnosis, diagnosed with NHL vs ALL, treated by adult hematologist/oncologists only (vs pediatric hematologist/oncologists), and of non-Hispanic Black race/ethnicity (vs non-Hispanic White) (P < 0.05 for all). Interaction analyses indicate improved clinical trial enrollment from 2006 to 2012-2013 among young adults 25-29 years of age and the uninsured.

conclusionsAlthough disparities in enrollment onto clinical trials remain for AYAs with cancer, our study identified increasing overall clinical trial participation over time. Further, we identify promising trends in enrollment uptake among AYAs 25-29 years of age and the uninsured.

Indexed as

Patient SelectionAdolescentAdultCancer Care FacilitiesClinical Trials as TopicFemaleHumansMaleNeoplasmsPatient ParticipationResearch SubjectsTime FactorsUnited StatesYoung Adult

Identifiers

PMID30256525
PMCPMC6249090

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.